Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Stock analysts at Leerink Swann decreased their Q3 2017 earnings per share estimates for shares of Amicus Therapeutics in a research note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will post earnings per share of ($0.30) for the quarter, down from their prior forecast of ($0.28). Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2017 earnings at ($0.30) EPS, FY2017 earnings at ($1.31) EPS, FY2018 earnings at ($1.06) EPS, FY2019 earnings at ($0.78) EPS and FY2020 earnings at ($0.55) EPS.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The company had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period last year, the business posted ($0.40) EPS.

COPYRIGHT VIOLATION WARNING: “Leerink Swann Comments on Amicus Therapeutics, Inc.’s Q3 2017 Earnings (FOLD)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/15/leerink-swann-comments-on-amicus-therapeutics-inc-s-q3-2017-earnings-fold.html.

FOLD has been the topic of a number of other research reports. BidaskClub downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 2nd. Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Bank of America Corporation lowered their target price on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Cowen and Company restated a “buy” rating and issued a $16.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Finally, Robert W. Baird restated an “outperform” rating and issued a $12.00 target price on shares of Amicus Therapeutics in a research note on Friday, June 30th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $14.75.

Amicus Therapeutics (FOLD) opened at 13.43 on Friday. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $14.36. The stock has a 50 day moving average price of $13.18 and a 200-day moving average price of $9.72. The stock’s market capitalization is $2.21 billion.

Large investors have recently made changes to their positions in the business. Teacher Retirement System of Texas lifted its position in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 169 shares during the last quarter. Princeton Alpha Management LP acquired a new stake in shares of Amicus Therapeutics in the first quarter worth about $106,000. DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in shares of Amicus Therapeutics in the second quarter worth about $111,000. Tudor Investment Corp ET AL acquired a new stake in shares of Amicus Therapeutics in the second quarter worth about $124,000. Finally, Aperio Group LLC lifted its position in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,663 shares during the last quarter.

In related news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of Amicus Therapeutics stock in a transaction on Thursday, July 13th. The stock was bought at an average price of $12.25 per share, with a total value of $18,375,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jay Barth sold 30,000 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $10.00, for a total value of $300,000.00. Following the completion of the sale, the insider now directly owns 64,184 shares of the company’s stock, valued at approximately $641,840. The disclosure for this sale can be found here. 3.40% of the stock is owned by insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.